Why the study?
How is anticoagulant therapy initiated and monitored in inpatients with DVT or PE?
How is anticoagulant therapy initiated and monitored in inpatients with DVT or PE?
This retrospective study highlights suboptimal initiation and monitoring of anticoagulant therapy for DVT/PE, with low rates of therapeutic INR at discharge and a high rate of adverse outcomes.
Suboptimal INR at DVT/PE discharge was associated with adverse events; leaves open whether protocolized monitoring reduces risks in prospective studies.
The objective was to retrospectively study the initiation of anticoagulant therapy in inpatients of the two major teaching hospitals in Tasmania, Australia. The medical records of a random sample of patients with an admission diagnosis of deep venous thrombosis (DVT) or pulmonary embolism (PE) during the period February 1992 to June 1994 were studied, to examine therapeutic issues including (i) the time taken after commencing heparin to achieve a therapeutic activated partial thromboplastin time (APTT), (ii) when warfarin was commenced, (iii) the time taken after commencing warfarin to achieve a therapeutic International Normalized Ratio (INR), and (iv) the degree of anticoagulant control at the time of discharge from hospital. The medical records of 99 patients (median age: 65 years and range: 16–93 years; 52 females) were studied. Heparin was generally commenced within 4 h of admission to hospital. The median duration of heparin therapy was 5 days (range: 2–26 days). The median number of APTTs performed per patient was 6 (range: 1–24), with most results (60%) being below the optimum range. Warfarin was commenced from day 1 of hospitalization in only 34% of patients. The INR was within the therapeutic range in only 29% of cases when heparin was ceased. The median time taken to achieve a therapeutic INR after starting warfarin was 3 days (range: 1–15 days). The median number of INRs performed per patient was 5 (range: 1–29), with most results (51%) being below the optimum range. The INR was within the therapeutic range in only 55% of cases at discharge. An adverse outcome (bleeding or further clotting) was experienced by 19% of patients. This study has revealed considerable scope for improvement in some aspects of the initiation of anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
Corbett et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: